About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Drs. Chang and Chagan review posaconazole (Noxafil) for fungal infections.
Mei Chang, BA, PharmD, and Larisa Chagan, PharmD, BCPS
An in-depth interview with the director of the FDA’s Center for Drug Evaluation and Research reveals a conscientious leader who is receiving high marks for her candor about the agency’s challenges.
Presentations cover therapies for breast cancer, renal cell carcinoma, chronic myelogenous leukemia, non–small-cell lung cancer, bone resorption, and melanoma.
Continuing Education Credit
Migraine is the most common headache complaint in clinical practice. Part 1 of a two-part series presents a summary of treatments used to reduce the severity and duration of migraine and its associated symptoms and also discusses the comorbidities, clinical presentation, and risk factors associated with this affliction.
George DeMaagd, PharmD, BCPS
In 2001, The Joint Commission released new pain guidelines and attempted to address the problem of undertreated pain; however, the resulting focus on the pain score number has inadvertently led to some serious adverse drug events. In addition, the recent dramatic increase in opioid use has resulted in greater abuse of these prescribed drugs, often by teenagers.
Steven Hanks, MD, MMM, FACP
David Nash, MD, MBA, debunks four myths about health care spending. For instance, it is widely known that the U.S. spends more on health care than other nations, but this is not because of drug costs or doctor fees.
David B. Nash, MD, MBA
Matthew Grissinger, RPh, FASCP, describes common mishaps that can occur with lomustine (CCNU), a drug used to treat Hodgkin’s disease and brain cancer.
Matthew Grissinger, RPh, FASCP
Stephen Barlas wonders whether offering money to doctors who switch to electronic prescriptions will be enough of an incentive.
From becaplermin to zoledronic acid, P&T presents the latest information about FDA approvals, new indications, recalls, and industry updates.